Skip to main content

Table 5 Overview of treatment emergent adverse events (SAF, n = 24)

From: Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial

  Total Untreated 2.8 mg dose 5.5 mg dose 11.0 mg dose
  (N = 24) (N = 24) (N = 18) (N = 19) (N = 20)
  N (%)a n N (%)a n N (%)a n N (%)a n N (%)a n
All TEAEs 23 (95.8) 77 16 (66.7) 24 10 (55.6) 17 11 (57.9) 21 10 (50.0) 15
Severe 1 (4.2) 1    1 (5.3) 1  
Possibly related 4 (16.7) 7   1 (5.6) 1 3 (15.8) 6  
Related 2 (8.3) 2    1 (5.3) 1 1 (5.0) 1
  1. AE adverse event, N number of subjects, n number of events, SAF safety analysis set, TEAE treatment emergent adverse event
  2. aPercentages are based on the total number of subjects
\